View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 21, 2021

UBC begins mix-and-match study of Covid-19 vaccines in Canada

The University of British Columbia is set to study the effects of mixing different Covid-19 vaccines.

The University of British Columbia (UBC) has started a clinical study to assess the effects of mixing different brands of approved Covid-19 vaccines in Canada.

Named MOSAIC, the study will examine the safety and effectiveness of two separate vaccines for the first and second doses. It is also intended to evaluate increased intervals between two doses.

The study will enrol a total of 1,300 subjects at Canadian Immunization Research Network (CIRN) sites across Nova Scotia, Quebec, Ontario, Manitoba, Alberta and British Columbia.

CIRN principal investigator Dr Scott Halperin said: “Soon after vaccine rollout programmes began, manufacturing interruptions resulted in delayed vaccine shipments to various countries, including Canada.

“This study will give public health officials more information about how to manage their vaccine roll-out strategies going forward.”

The Canadian Government is supporting the study with $3.9m (C$4.8m) funding via the COVID-19 Immunity Task Force (CITF) and the Vaccine Surveillance Reference Group (VSRG).

Currently, four Covid-19 vaccines are approved in Canada, including three vaccines distributed by public health programmes. Other vaccines will be added to the study upon approval and availability.

Data from the MOSAIC study will be reported to public health officials to inform vaccine rollout decisions in the country.

UBC faculty of medicine dean and health vice-president Dr Dermot Kelleher said: “This research will provide critical scientific insight into the safety and effectiveness of mixing and matching Covid-19 vaccines, and could pave the way for a more flexible approach to vaccine rollouts taking place across the country.”

Similar mix-and-match Covid-19 vaccine studies are ongoing in other countries, including the UK. South Korea has also started a clinical trial to mix Covid-19 vaccines of various companies, including AstraZeneca and Pfizer.

This announcement comes a day after the UK launched a new clinical trial to assess a third ‘booster’ dose of seven different Covid-19 vaccines.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy